AU2010220722B2 - Salts of tetrahydroimidazo [1,5-a] pyrazine derivatives, preparation methods and pharmaceutical use thereof - Google Patents
Salts of tetrahydroimidazo [1,5-a] pyrazine derivatives, preparation methods and pharmaceutical use thereof Download PDFInfo
- Publication number
- AU2010220722B2 AU2010220722B2 AU2010220722A AU2010220722A AU2010220722B2 AU 2010220722 B2 AU2010220722 B2 AU 2010220722B2 AU 2010220722 A AU2010220722 A AU 2010220722A AU 2010220722 A AU2010220722 A AU 2010220722A AU 2010220722 B2 AU2010220722 B2 AU 2010220722B2
- Authority
- AU
- Australia
- Prior art keywords
- acid
- salt
- tetrahydro
- trifluoromethyl
- pyrazine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910047075A CN101824036A (zh) | 2009-03-05 | 2009-03-05 | 四氢咪唑并[1,5-a]吡嗪衍生物的盐,其制备方法及其在医药上的应用 |
| CN200910047075.4 | 2009-03-05 | ||
| PCT/CN2010/000257 WO2010099698A1 (zh) | 2009-03-05 | 2010-03-03 | 四氢咪唑并[1,5-a]吡嗪衍生物的盐,其制备方法及其在医药上的应用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2010220722A1 AU2010220722A1 (en) | 2011-10-27 |
| AU2010220722A2 AU2010220722A2 (en) | 2011-11-03 |
| AU2010220722B2 true AU2010220722B2 (en) | 2015-05-07 |
Family
ID=42688223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2010220722A Ceased AU2010220722B2 (en) | 2009-03-05 | 2010-03-03 | Salts of tetrahydroimidazo [1,5-a] pyrazine derivatives, preparation methods and pharmaceutical use thereof |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8518946B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2404921B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5976322B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101731602B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN101824036A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2010220722B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2753862C (cg-RX-API-DMAC7.html) |
| MX (1) | MX2011009190A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2523543C2 (cg-RX-API-DMAC7.html) |
| UA (1) | UA106225C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2010099698A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201107284B (cg-RX-API-DMAC7.html) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101899048B (zh) * | 2009-05-27 | 2013-04-17 | 上海恒瑞医药有限公司 | (R)-7-[3-氨基-4-(2,4,5-三氟-苯基)-丁酰]-3-三氟甲基-5,6,7,8-四氢-咪唑并[1,5-a]吡嗪-1-羧酸甲酯的盐 |
| CN106892926B (zh) * | 2012-10-16 | 2019-09-06 | 江苏盛迪医药有限公司 | 一种dpp-iv抑制剂的中间体、其制备方法和通过其制备dpp-iv抑制剂的方法 |
| CN103664962A (zh) * | 2013-12-20 | 2014-03-26 | 南京华威医药科技开发有限公司 | 哌嗪类衍生物 |
| CN103910734B (zh) * | 2014-03-28 | 2016-01-13 | 南京华威医药科技开发有限公司 | 一种具有哌嗪结构的dpp-4抑制剂 |
| CN114702495A (zh) | 2015-11-20 | 2022-07-05 | 福马治疗有限公司 | 作为泛素-特异性蛋白酶1抑制剂的嘌呤酮 |
| CN119613408A (zh) | 2017-07-14 | 2025-03-14 | 豪夫迈·罗氏有限公司 | 二环酮化合物及其使用方法 |
| MX2020003451A (es) | 2017-10-31 | 2020-08-03 | Hoffmann La Roche | Sulfonas y sulfoxidos biciclicos y metodos de uso de los mismos. |
| WO2020139988A1 (en) * | 2018-12-28 | 2020-07-02 | Forma Therapeutics, Inc. | Compositions for inhibiting ubiquitin specific protease 1 |
| CN113620957B (zh) * | 2020-05-08 | 2022-04-19 | 盛世泰科生物医药技术(苏州)有限公司 | 一种胺甲基吡嗪类化合物的制备方法 |
| CN113773323B (zh) * | 2020-06-10 | 2023-05-12 | 江苏恒瑞医药股份有限公司 | 3r-氨基取代丁酰胺衍生物的制备方法 |
| CN113880825B (zh) * | 2020-07-01 | 2025-03-14 | 浙江海正药业股份有限公司 | 四氢异喹啉类衍生物的盐、其制备方法及其医药应用 |
| JP2024504328A (ja) * | 2021-01-21 | 2024-01-31 | ザ スクリプス リサーチ インスティテュート | 肺疾患の治療のための肺胞2型細胞増殖の小分子調節因子 |
| CN114057751B (zh) * | 2022-01-17 | 2022-04-12 | 盛世泰科生物医药技术(苏州)有限公司 | 一种dpp-iv抑制剂及其关键中间体的制备方法 |
| CN115583935A (zh) * | 2022-11-03 | 2023-01-10 | 浙江工业大学 | 一种4-(2,4,5-三氟苯基)-3-氧丁酸酯的制备方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008342461A1 (en) * | 2007-12-26 | 2009-07-09 | Jiangsu Hengrui Medicine Co., Ltd. | Tetrahydro-imidazo(1,5-a)pyrazine derivatives, preparation methods and medical uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW492957B (en) | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
| FR2780974B1 (fr) * | 1998-07-08 | 2001-09-28 | Sod Conseils Rech Applic | Utilisation de derives d'imidazopyrazines pour preparer un medicament destine a traiter les pathologies qui resultent de la formation de la proteine g heterotrimetrique |
| US6110949A (en) | 1999-06-24 | 2000-08-29 | Novartis Ag | N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
| UA74912C2 (en) * | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
-
2009
- 2009-03-05 CN CN200910047075A patent/CN101824036A/zh active Pending
-
2010
- 2010-03-03 MX MX2011009190A patent/MX2011009190A/es active IP Right Grant
- 2010-03-03 JP JP2011552307A patent/JP5976322B2/ja not_active Expired - Fee Related
- 2010-03-03 UA UAA201110708A patent/UA106225C2/ru unknown
- 2010-03-03 WO PCT/CN2010/000257 patent/WO2010099698A1/zh not_active Ceased
- 2010-03-03 KR KR1020117020764A patent/KR101731602B1/ko not_active Expired - Fee Related
- 2010-03-03 AU AU2010220722A patent/AU2010220722B2/en not_active Ceased
- 2010-03-03 CA CA2753862A patent/CA2753862C/en not_active Expired - Fee Related
- 2010-03-03 EP EP10748288.7A patent/EP2404921B1/en not_active Not-in-force
- 2010-03-03 RU RU2011137858/04A patent/RU2523543C2/ru not_active IP Right Cessation
- 2010-03-03 CN CN2010800026815A patent/CN102159578B/zh active Active
-
2011
- 2011-09-02 US US13/225,050 patent/US8518946B2/en not_active Expired - Fee Related
- 2011-10-05 ZA ZA2011/07284A patent/ZA201107284B/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008342461A1 (en) * | 2007-12-26 | 2009-07-09 | Jiangsu Hengrui Medicine Co., Ltd. | Tetrahydro-imidazo(1,5-a)pyrazine derivatives, preparation methods and medical uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| US8518946B2 (en) | 2013-08-27 |
| CN102159578B (zh) | 2013-04-10 |
| KR101731602B1 (ko) | 2017-04-28 |
| RU2011137858A (ru) | 2013-04-10 |
| EP2404921A1 (en) | 2012-01-11 |
| AU2010220722A2 (en) | 2011-11-03 |
| AU2010220722A1 (en) | 2011-10-27 |
| CA2753862A1 (en) | 2010-09-10 |
| EP2404921A4 (en) | 2012-08-15 |
| US20120065209A1 (en) | 2012-03-15 |
| HK1154574A1 (en) | 2012-04-27 |
| CN101824036A (zh) | 2010-09-08 |
| ZA201107284B (en) | 2012-12-27 |
| WO2010099698A1 (zh) | 2010-09-10 |
| KR20110132561A (ko) | 2011-12-08 |
| UA106225C2 (ru) | 2014-08-11 |
| CN102159578A (zh) | 2011-08-17 |
| MX2011009190A (es) | 2011-09-26 |
| JP2012519193A (ja) | 2012-08-23 |
| EP2404921B1 (en) | 2017-11-22 |
| JP5976322B2 (ja) | 2016-08-23 |
| CA2753862C (en) | 2017-05-23 |
| RU2523543C2 (ru) | 2014-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2404921B1 (en) | SALTS OF TETRAHYDROIMIDAZO[1,5-a]PYRAZINE DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL USE THEREOF | |
| JP2012519193A5 (cg-RX-API-DMAC7.html) | ||
| KR101685103B1 (ko) | 테트라하이드로-이미다조[1,5-a]피라진 유도체, 이의 제조 방법 및 의학적 용도 | |
| KR20150003875A (ko) | 바독솔론 메틸의 2,2-다이플루오로프로피온아미드 유도체, 그의 다형태 및 사용 방법 | |
| EP3983384A1 (en) | N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as gpr17 modulators for treating cns disorders such as multiple sclerosis | |
| CN116157401B (zh) | 杂环类衍生物及其制备方法和用途 | |
| JP5661177B2 (ja) | ヘキサヒドロピロロ[3,4−b]ピロール誘導体、その製造方法及び用途 | |
| TWI522358B (zh) | 四氫咪唑并〔1,5-a〕吡衍生物的鹽,其製備方法及其在醫藥上的應用 | |
| TWI439271B (zh) | 四氫咪唑並〔1,5-a〕吡類衍生物,其製備方法及其在醫藥上的應用 | |
| WO2008148279A1 (en) | Cyclobutyl-fused pyrrolidine derivatives, their preparation methods and their medical use | |
| HK1154574B (en) | Salts of tetrahydroimidazo [1,5-a] pyrazine derivatives, preparation methods and pharmaceutical use thereof | |
| RU2819762C1 (ru) | Соединение в качестве ингибитора циклинзависимой киназы 9 и его применение | |
| TW202615049A (zh) | 用於治療疾病或障礙的氫喹唑啉衍生物 | |
| CN121226332A (zh) | 1,2,3-三氮唑类化合物及其作为apj受体激动剂的用途 | |
| HK1134817B (en) | Tetrahydro-imidazo[1,5-a]pyrazine derivatives, preparation methods and medical uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 29 SEP 2011 |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |